Lisata Therapeutics Hits New 52-Week High of $5.06

Lisata Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.06 on March 9, 2026. This achievement marks a notable increase from its 52-week low of USD 1.81, reflecting a robust one-year performance of 46.09%, significantly outperforming the S&P 500, which recorded a gain of 17.78% during the same period. Despite being a loss-making entity, Lisata Therapeutics has shown resilience in a competitive market, with a market capitalization of USD 40 million. The company currently has a price-to-book ratio of 2.28, indicating its valuation relative to its assets. However, it is important to note that the company does not offer a dividend yield and has a negative debt-to-equity ratio of -1.09, alongside a return on equity of -105.00%. These metrics highlight the company's current financial standing and market position as it continues to navigate the dynamic landscape of the biotechnology industry.